14th European Congress of Clinical Microbiology and Infectious ...

Monday,
May 3, 2004
Tuesday,
May 4, 2004
Scientific Programme Overview
07
08
09
10
11
12
13
14
15
16
17
07
08
09
10
11
12
13
14
15
16
Auditorium
Ground Floor
Small Hall Panorama Hall
07.15 – 08.15
How to advise the
travelling pregnant
woman and
her children
10.00 – 12.00
Acute
exacerbation of
chronic bronchitis:
an insidious
infection
12.15 – 13.45
ESGT
Business
meeting
15.30 – 17.30
Antibiotic
resistance,
prevention
and control in
Europe
page 20 Final Programme
10.00 – 12.00
The changing
faces of
S. aureus
15.30 – 17.30
Group A
streptococcal
disease in the
21 st century
1st Floor
Meeting Hall I Club A
10.00 – 12.00
New
technologies for
microbiological
diagnostics
12.15 – 13.45
ESGARS
Business
meeting
15.30 – 17.30
Rational
antibiotic use:
the future of
LRTI treatment
Pfizer
07.15 – 08.15
New strategies in
the management
of Hepatitis B&C
10.00 – 12.00
Molecular
epidemiology
and management
of nosocomial
outbreaks
12.15 – 13.45
ESCAR
Business
meeting
2nd Floor
Forum Hall
14.00 – 15.00
14.00 – 15.00
14.00 – 15.00
14.00 – 15.00
14.00 – 15.00
Toxoplasmosis in Guidelines for European recommen- Treatment of Viral
the immunocompromised
host
lower respiratory dations for antibiotic
tract infections resistance surv.
invasive fungal
infections
encephalitis
p. 49 p. 49 p. 49 p. 50 p. 49
15.30 – 17.30
Novel advances
in antifungal
therapy
Vicuron
10.00 – 12.00
Effective use
of carbapenems
in the management
of hospitalised
patients with
community
acquired infections
Aventis
p. 47 p. 44 p. 44 p. 45 Merck p. 47
10.00 – 12.00
Cancer and
infection:
a two-way road
12.15 – 13.45
EHSG
Business
meeting
14.00 – 16.00
Biofilms
15.30 – 17.30
Lyme
borreliosis
p. 51 p. 000 51 p. 55 p. 55 p. 51
10.00 – 12.00
Vectortransmitted
diseases in
the tropics
12.15 – 13.45
EFISG
Business
meeting
14.00 – 16.00
Current
problems in
clinical
mycology
08.30 – 09.30 �Mapping the
co-evolution of man
and H. pylori
p. 43 p. 43
p. 25 p. 25 p. 25
10.00 – 12.00
Clinical
implications of
early antifungal
therapy
Pfizer
p. 57
14.00 – 16.00
Antimicrobial
susceptibility
testing of
difficult
organisms
10.00 – 12.00
Antibiotic
resistance:
from ESBL to
fluoroquinolones
12.15 – 13.45
ESGCD
Business
meeting
10.00 – 12.00
The clinical
relevance of
rapid
diagnostics
p. 57 p. 57 p. 60 p. 58 p. 57
12.15 – 13.45
ESGMD
Business
meeting
p. 25 p. 25 p. 25 p. 25
p. 62 p. 62 p. 62
08.30 – 09.30
Global pandemics: �
emerging infectious
diseases
p. 44 p. 44
07.15 – 08.15
07.15 – 08.15
How to prepare and
deliver scientific
communication
p. 56
08.30 – 09.30 �Meningococcal infection:
still a challenge
in the 21
New developments
in the diagnosis
of invasive mycoses
p. 56
08.30 – 09.30
Evolutionary �
engineering of antibiotic
resistance
st century
p. 57